Altogether, our data point to subunits of the 19S proteasome as novel prognostic biomarkers and putative targets for therapy in FLT3+ AML, CML, and other types of cancers that are worthy of future investigation. This evidence concerns the gene FLT3 and chronic myelogenous leukemia, BCR-ABL1 positive.